Download fulltext HTML

https://doi.org/10.18502/espoch.v1i6.9660

statistics

  • 409 Abstract Views
  • 394 PDF Views
  • 0 HTML Views

authors

  • Marcelo Ramiro Montúfar Silva

    Marcelo Ramiro Montúfar Silva

    Docente ESPOCH Médico Internista, Riobamba, Ecuador
  • Jessica Paola Cevallos Montalvo

    Jessica Paola Cevallos Montalvo

    Medico Posgradista de Dermatología, Riobamba, Ecuador
  • Byron Mauricio Sánchez Andino

    Byron Mauricio Sánchez Andino

    Médico Internista
  • María Johanna Jima Sanchez

    María Johanna Jima Sanchez

    Médico Internista
  • Cecilia Alejandra García Ríos

    Cecilia Alejandra García Ríos

    Docente ESPOCH, Pediatra, Riobamba, Ecuador

Published Date

  • Sep 9, 2021

Relationship Between Thyroid Cancer and Hashimoto's Disease

ESPOCH Congresses: The Ecuadorian Journal of S.T.E.A.M. / Volume 1, Issue 6 / Pages 1698–1704

Abstract

Introduction: Globally, Ecuador ranks fifth among the countries with the highest incidence of thyroid carcinoma in women, below Korea, Brazil, Italy and New Celedonia. The aim of this research was to mention the relationship between thyroid cancer and Hashimoto's thyroiditis at Pablo Arturo Suárez Hospital in Quito in the years 2014 to 2017. Methodology: A cross sectional study was conducted. The data were taken from the clinical records in the statistical service, 105 cases of thyroid cancer were found.  In the laboratory results 21 patients had anti TPO and/or anti TG positive antibodies. Conclusion: 20% of patients with thyroid cancer had a history of Hashimoto's thyroiditis.


Keywords: thyroid cancer, Hashimoto's thyroiditis, autoimmune thyroiditis.


RESUMEN

Introducción: A nivel mundial el Ecuador ocupa el quinto lugar entre los países con mayor incidencia de carcinoma de tiroides en mujeres, por debajo de Corea, Brasil, Italia y Nueva Celedonia. Objetivo: El objetivo de la presente investigación fue mencionar la relación entre cáncer de tiroides y tiroiditis de Hashimoto en el Hospital Pablo Arturo Suárez de la ciudad de Quito en los años 2014 a 2017. Metodología: se desarrolló un estudio de tipo transversal los datos se tomaron de los expedientes clínicos en el servicio de estadística, donde se encontró 105 casos de estudios histopatológicos compatibles con neoplasia tiroidea. Resultados: En los resultados de laboratorio se evidenció que 21 pacientes tuvieron anticuerpos anti TPO y/o anti TG positivos. Conclusión: El 20% de pacientes con cáncer de tiroides tuvieron antecedente de enfermedad autoinmune tiroidea.


Palabras clave: cáncer de tiroides, tiroiditis de Hashimoto, tiroiditis autoinmune.

References
[1]Gardner D, Shobck D. Greenspan´s basic and clinical endocrinology. 9th ed. Mexico: McGraw‐Hill Companies; 2011. p. 217‐226.

[2]Aschebrook‐Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid. 2011;21(2):125–134.

[3]Mincer DL, Jialal I. Hashimoto Thyroiditis. StatPearls;2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459262/

[4]Fulciniti F, Barizzi J, Trimboli P, Giovanella L. Solid papillary thyroid carcinoma with Hashimoto’s thyroiditis: description of a further case with challenging cytological features. BMJ Case Rep. 2019;12(1).

[5]Leni A, Vita R, Magliolo E, et al. One-third of an archivial series of papillary thyroid cancer (years 2007–2015) has coexistent chronic lymphocytic thyroiditis, which is associated with a more favorable tumor‐node‐metastasis staging. Front Endocrinol. 2017;8(337):1‐7.

[6]Slijepcevic N, Zivaljevic V, Marinkovic J, Sipetic S, Diklic A, Paunovic I. Retrospective evaluation of the incidental finding of 403 papillary thyroid microcarcinomas in 2466 patients undergoing thyroid surgery for presumed benign thyroid disease. BMC Cancer. 2015;15(330).

[7]Akin S, Yazgan AD, Akin S, Kilic M, Yetisir F, Bayraktar M. Prediction of central lymph node metastasis in patients with thyroid papillary microcarcinoma. Turk J Med Sci. 2017;47(6):1723–7.

[8]Baser H, Ozdemir D, Cuhaci N, et al. Hashimoto's thyroiditis does not affect ultrasonographical, cytological, and histopathological features in patients with papillary thyroid carcinoma. Endocr Pathol. 2015;26(4):356–64.

[9]Lai X, Zhang B, Jiang Y, et al. Sonographic and clinical features of papillary thyroid microcarcinoma less than or equal to five millimeters: a retrospective study. PloS One. 2016;11(2).

[10] Myshunina T, Guda B, Bolgov M, Mikhailenko N, Tronko N. Differentiated thyroid carcinomas associated with chronic thyroiditis: biological and clinical properties. Exp Oncol. 2018;40(2):128–31.

[11] Paparodis R, Imam S, Todorova‐Koteva K, Satii A, Jaume J. Hashimoto’s Thyroiditis pathology and risk for thyroid cancer. Thyroid. 2014;24(7):1107‐14.

[12] Girardi FM, Barra MB, Zettler CG. Papillary thyroid carcinoma: Does the association with Hashimoto's thyroiditis affect the clinicopathological characteristics of the disease. Braz J Otorhinolaryngol. 2015;81(3):283‐7.

[13] Vita R, Leni A, Tuccari G, Benvenga S. The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma. Rev Endocr Metab Disord. 2018;19(4):301‐9.

[14] Ehlers M, Schott M. Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked? Trends
Endocrinol Metab. 2014;25(12):656-64.

[15] Ib L, Salas VM. Actualización de patología tiroidea 2017. AePap; 2017. p. 161–74.

[16] Es QUÉ, Glándula LA, Son C, Del LOSS, Tiroides PDE. Linfoma primario de la tiroides linfoma primario de la tiroides. 2018.

[17] Yi JW, Park JY, Sung JY, et al. Genomic evidence of reactive oxygen species elevation in papillary thyroid carcinoma with Hashimoto thyroiditis. Endocr J. 2015;62(10):857‐77.

[18] Félix J, Ramos R. Risk factors for thyroid diseases: Ambato Social Security Hospital in Ecuador. Revista Ciencias médicas Pinar del Rio. 2016;20(5):628–38.

[19] Piraino PN, Sepúlveda AN, Cavada GC. Tiroiditis crónica de Hashimoto. serie clínica. Rev Med Chil. 2010;138(7):827– 31.

[20] Álvarez G, Delgado J. Diseno de Estudios Epidemiológicos. I. El estudio transversal: Tomadondo una fotografía de la salud y la enfermedad. Bol Clin Hosp Infant Endo Son. 2015;32(1):26–34.

[21] Rodríguez M, Mendivelso F. Diseño de investigación de Corte Transversal. Rev Médica Sanitas. 2018;21(3):141–6.

[22] Manterola C, Otzen T. The most commonly used designs in clinical research. Int J Morphol. 2014;32(2):634–45.

[23] Gutiérrez‐Pérez RB, Salgado ML. Evaluación de la disfunción tiroidea en estudiantes de una institución universitaria Evaluation of thyroid dysfunction in university students of an institution. Rev Salud Pública. 2016;18(6):926–34.

[24] Akdi A. Susceptibilidad genética al cáncer de tiroides: Estudios de asociación de las regiones del genoma 1p12 Y 8q. Bellaterra: Universidad Autónoma de Barcelona; 2011. 23 p.

[25] Casos GSDE. By gammagraphy. Series of cases introducción. 2010; 18(40):235–40.

[26] Lima PCM, Moura NA, Tambascia MA, Zantut Wittmann DE. Risk factors associated with benign and malignant thyroid nodules in autoimmune thyroid diseases. ISRN Endocrinol. 2013;2013(673146):1–7.

[27] Sáez MGJ. Hashimoto’s Thyroiditis and thyroid cancer. Hum Endocrinol. 2017; 1(1):1–4.

[28] Penta L, Cofini M, Lanciotti L, Leonardi A, Principi N, Esposito S. Hashimoto’s disease and thyroid cancer in children: Are they associated? Front Endocrinol (Lausanne). 2018;9(565):1–5.

[29] Hershman JM. Patients with differentiated thyroid cancer and coexistent hashimoto’s thyroiditis have a better prognosis than those without thyroiditis. Clin Thyroidol. 2013;25(10):225–6.

[30] Cipolla C, Sandonato L, Graceffa G, et al. Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg. 2005;71(10):874–8.